Skip to main content

M16-573 A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane
Therapy in Adults with Relapsed and/or Refractory Solid Tumors.

NCT03595059

A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane
Therapy in Adults with Relapsed and/or Refractory Solid Tumors.

Associated Conditions

Multiple Tumor Types

Principal Investigator

George Simon

Sponsor

AbbVie

You have been asked to participate in this research study because you have been diagnosed with relapsed and/or refractory cancer; cancer that has returned after treatment or the cancer has not responded to treatment. Depending on your type of cancer, you will be administered an investigational drug called Mirzotamab Clezutoclax either alone or in combination with either paclitaxel or docetaxel. An investigational drug is one that has not been approved for sale in the United States by the U.S. Food and Drug Administration (FDA). Paclitaxel is approved for ovarian, breast, and non small cell lung cancers (alone or combination with other drugs). Docetaxel is approved for breast, non small cell lung, prostate, gastric, head and neck cancers (alone or combination with other drugs).

This study is currently enrolling.